We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- View the Talks
-
1. In vitro drug screening
- Dr. Wayne Carter
-
2. In vivo drug screening
- Dr. Wayne Carter
-
3. Clinical trials
- Dr. Wayne Carter
Printable Handouts
Navigable Slide Index
Topics Covered
- Drug testing in humans
- Different phases of clinical trials
- Maximum tolerated dose (MTD)
- Efficacy and safety of clinical trials
Links
Series:
Categories:
Talk Citation
Carter, W. (2025, October 30). Clinical trials [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved January 15, 2026, from https://doi.org/10.69645/GMFP6025.Export Citation (RIS)
Publication History
- Published on October 30, 2025
Financial Disclosures
- There are no commercial/financial matters to disclose.
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Dr. Wayne Carter.
The title of this lecture
is Clinical Trials.
0:08
Drug testing in humans.
Drug testing in humans is
initiated after
compound optimisation,
after the formulation
has been developed,
and a route of
administration has been
finalised in an animal model.
There's a need to establish
a safety and efficacy
profile prior to
market approval of the drug.
Clinical trials are
undertaken and separated into
four milestones: Phases I to IV.
0:37
Phases of clinical trials.
In phase I,
a safety profile and
pharmacokinetics are established.
In phase II,
using a pilot or a relatively
low number of humans,
studies are undertaken to
establish safety and efficacy in
the target patient population.
In phase III,
a larger human study
is undertaken in
the target population to
further establish
safety and efficacy,
and establish the benefit
and efficacy versus
the risk of adverse effects.
In phase IV, this is
a post-approval safety and
drug effectiveness follow-up.
1:17
Phase I, safety first.
First-in-human, that is phase I,
provides a provisional
test of safety and
may also consider efficacy.
A single ascending dose (SAD) or
multiple ascending dose
(MAD) is undertaken to
determine the maximum
tolerated dose (MTD) that
produces dose-limiting toxicity,
in other words, side effects.
This provides an insight into
also the human
pharmacokinetic profile.
Typically, this is
undertaken with
healthy volunteers
(20 to 100) and
can take up to 18
months to complete.
It can be undertaken to consider
a test group versus a placebo
group, but not always.
But the results are obtained and
provide the basis
for phase II dosing.